45
Participants
Start Date
May 23, 2023
Primary Completion Date
January 30, 2028
Study Completion Date
January 30, 2030
GPC2 CAR T cells
The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
Collaborators (1)
Children's Hospital of Philadelphia
OTHER
Gilead Sciences
INDUSTRY
University of Pennsylvania
OTHER
National Cancer Institute (NCI)
NIH
Kite, A Gilead Company
INDUSTRY
Stephan Grupp MD PhD
OTHER